The US Department of Agriculture approved the genetically modified purple tomato to extend its shelf life and boost nutritional quality almost 15 years after its development.
According to biochemist Cathie Martin, she and her colleagues at Norfolk Plant Scientists (NPS) have been experimenting with pigment production in flowering plants for over two decades, and they've spent almost 15 months developing the purple tomato.
The NPS has been focusing on anthocyanins, the antioxidant-rich pigments that give blackberries and blueberries their signature shades.
Domesticated tomatoes already have genes to produce anthocyanins, but they are not 'turned on.' By carefully adding two genes, the tomatoes and juice become a rich source of antioxidants, because purple pigments are made in the whole tomato, not just the skins.
While there are already some purple-skinned tomatoes, their pigments mostly stop at the outer layers and don't accumulate in the fruit itself.
The NPS also emphasized that there is increasing evidence to show that antioxidants work much better when consumed within foods.
The USDA Animal and Plant Health Inspection Service (APHIS) reported that the tomato was modified to alter its color and enhance its nutritional quality, adding that the plant is unlikely to pose an increased plant pest risk compared to other cultivated tomatoes.
Nathan Pumplin, the CEO of NPS' US-based commercial business, said they are optimistic that they can begin limited distribution of purple tomatoes in the US by 2023.


NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern
US Dollar Slips After PCE Inflation Data as Fed Rate Hike Expectations Stay Elevated
Alphabet Replaces Verizon in Dow Jones Industrial Average
Morgan Stanley Sees Chinese Auto Market Recovery Gaining Momentum in Late Summer
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Why the future of marijuana legalization remains hazy despite high public support
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Wall Street Ends Lower as AI Stocks Drag Markets, Fed Rate Outlook Shifts
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028
Oil Prices Drop as Strait of Hormuz Shipping Recovers
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access
Asian Currencies Trade Mixed as Yen Hovers Near 40-Year Low, Dollar Holds Firm on Fed Outlook 



